Alberto Ortiz Lobo

The largest meta-analysis to date that studies the risk of children of people with a mental disorder also suffering from some type of mental disorder during their lifetime has been published, with Spanish participation. According to the study, the risk is more than double that of the rest of the population. To explain the study and resolve any doubts that may arise, the Science Media Centre Spain organised an information session with one of the authors, psychiatrist Joaquim Raduà.

An international team, led by the Hospital Clínic-IDIBAPS in Barcelona together with King's College London (UK) and Dalhousie University (Canada), has published the largest meta-analysis to date studying the risk of children of people with mental disorders developing the same, or another type of disorder. The study included more than three million children of parents with different types of disorders and more than 20 million people as a control population. The results, published in the journal World Psychiatry, indicate that, overall, the former have a 1.5 to 3 times higher risk of developing a disorder in their lifetime. According to the authors, in the case of bipolar, depressive or anxiety disorders, the risk of their offspring suffering from some type of disorder is more than 50%.

Apps developed to treat depression may be beneficial in the management of severe and moderate cases. This is the conclusion of a review and meta-analysis that included 13 studies with up to 16 different apps. The results are published in the journal JAMA Network Open.

A phase 1 clinical trial has tested the use of psilocybin to treat anorexia nervosa. Ten women with the disorder were given 25 milligrams of the hallucinogen along with psychological support. The results show that the treatment is safe and tolerable. Four patients showed an improvement, but the authors acknowledge that, because of the small sample size and the absence of a control group, "the results are preliminary and further research is needed". The results are published in the journal Nature Medicine.

A commentary published last Friday in the journal Molecular Psychiatry, signed by more than 30 researchers, challenges the conclusions of the systematic review published in the same journal in July 2022, in which the authors concluded that there was no evidence that low serotonin levels cause depression. The researchers in the new paper blame the earlier study for flaws in methodology, among other weaknesses.